Literature DB >> 33161529

Fasudil attenuates glial cell-mediated neuroinflammation via ERK1/2 and AKT signaling pathways after optic nerve crush.

Wei Huang1,2, Qianqian Lan1, Li Jiang1, Wenya Yan3, Fen Tang1, Chaolan Shen1, Hui Huang1, Haibin Zhong1, Jian Lv1, Siming Zeng1, Min Li1, Zhongxiang Mo4, Bing Hu4, Ning Liang4, Qi Chen1, Mingyuan Zhang4, Fan Xu5, Ling Cui6.   

Abstract

To investigate the functional role of fasudil in optic nerve crush (ONC), and further explore its possible molecular mechanism. After ONC injury, the rats were injected intraperitoneally either with fasudil or normal saline once a day until euthanized. RGCs survival was assessed by retrograde labeling with FluoroGold. Retinal glial cells activation and population changes (GFAP, iba-1) were measured by immunofluorescence. The expressions of cleaved caspase 3 and 9, p-ERK1/2 and p-AKT were detected by western blot. The levels of the pro-inflammatory cytokines were determined using real-time polymerase chain reaction. Fasudil treatment inhibited RGCs apoptosis and reduced RGCs loss demonstrated by the decreased apoptosis-associated proteins expression and the increased fluorogold labeling of RGCs after ONC, respectively. In addition, the ONC + fasudil group compared had a significantly lower expression of GFAP and iba1 compared with the ONC group. The levels of pro-inflammatory cytokines were significantly reduced in the ONC + fasudil group than in the ONC group. Furthermore, the phosphorylation levels of ERK1/2 and AKT (p-ERK1/2 and p-AKT) were obviously elevated by the fasudil treatment. Our study demonstrated that fasudil attenuated glial cell-mediated neuroinflammation by up-regulating the ERK1/2 and AKT signaling pathways in rats ONC models. We conclude that fasudil may be a novel treatment for traumatic optic neuropathy.

Entities:  

Keywords:  Fasudil; Neuroinflammation; Optic nerve crush; Retinal ganglion cells; p-AKT; p-ERK1/2

Mesh:

Substances:

Year:  2020        PMID: 33161529     DOI: 10.1007/s11033-020-05953-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  25 in total

Review 1.  [Essay on the development of traumatology].

Authors:  S S Tkachenko; Iu N Iur'ev; G V Akimov; G I Iushmanov
Journal:  Voen Med Zh       Date:  1974-10

2.  Cystic pulmonary lesions in patients with AIDS.

Authors:  D M Panicek
Journal:  Radiology       Date:  1989-10       Impact factor: 11.105

3.  Olives-craving in iron deficiency anemia.

Authors:  P Chandra; F Rosner
Journal:  Ann Intern Med       Date:  1973-06       Impact factor: 25.391

4.  Management of congenital adrenal hyperplasia.

Authors:  G Antony
Journal:  Lancet       Date:  1984-05-12       Impact factor: 79.321

Review 5.  [Treatment of decompensated cor pulmonale].

Authors:  N K Kazanbiev
Journal:  Sov Med       Date:  1981

6.  [Combination of rifampicin with amphotericin B in the treatment of paracoccidioidomycosis. Results in 3 treated patients].

Authors:  B Wanke; P N Pedrosa; G S Brêtas; S Setúbal
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1984 Jul-Aug       Impact factor: 1.846

7.  Entopeduncular nucleus projections to the contralateral thalamic nuclei: an HRP study.

Authors:  K Nakano; M Kohno; J Kawahira; A Tokushige
Journal:  Brain Res       Date:  1983-03-07       Impact factor: 3.252

8.  [Summary of 15-year experience in neonatal care--clinicopathologic study of 1,074 cases].

Authors: 
Journal:  Zhonghua Yi Xue Za Zhi       Date:  1974-01

9.  Expression of cytochromes P-450 in rat hepatoma cells. Analysis by monoclonal antibodies specific for cytochromes P-450 from rat liver induced by 3-methylcholanthrene or phenobarbital.

Authors:  F J Wiebel; S S Park; F Kiefer; H V Gelboin
Journal:  Eur J Biochem       Date:  1984-12-17
View more
  1 in total

1.  High Glucose Aggravates Retinal Endothelial Cell Dysfunction by Activating the RhoA/ROCK1/pMLC/Connexin43 Signaling Pathway.

Authors:  Hongran Zhao; Hui Kong; Wenjuan Wang; Tianran Chen; Yuting Zhang; Jing Zhu; Dandan Feng; Yan Cui
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-07-08       Impact factor: 4.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.